Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology.
To assess the clinical value of serum biochemical markers, the aminoterminal peptide of type III procollagen, type IV collagen 7S domain, the central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases, as a marker of hepatic fibrosis, we measured these four serum markers in 132 patients with chronic viral liver disease and compared these serum markers with liver histological findings. Serum levels of these markers increased closely with the progress of liver disease, and the abnormal percentages of type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with cirrhosis were 97%, 95%, 83% and 48%, respectively. These four serum markers strongly correlated with the histological degree of periportal with or without bridging hepatocellular necrosis and of liver fibrosis and correlated weakly with the degree of intralobular degeneration and focal necrosis and the degree of portal inflammation. The correlation coefficients of serum type IV collagen 7S domain with periportal with or without bridging hepatocellular necrosis and with liver fibrosis were the highest among these four serum markers, suggesting that serum type IV collagen 7S domain is the most valuable diagnostic marker to assess the degree of liver fibrosis in chronic viral liver disease. When we assessed the ability of each serum marker to detect cirrhosis with a receiver operating curve, the best test was type IV collagen 7S domain, and the second best was type III procollagen peptide.(ABSTRACT TRUNCATED AT 250 WORDS)
Murawaki
Y
Y
Second Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan.
Ikuta
Y
Y
Koda
M
M
Kawasaki
H
H
D000328:Adult; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D003094:Collagen / Q000097:blood* / Q000737:chemistry; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006525:Hepatitis, Viral, Human / Q000097:blood* / Q000150:complications / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology*; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000209:etiology / Q000473:pathology; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D008875:Middle Aged; D009336:Necrosis; D010446:Peptide Fragments / Q000097:blood; D011237:Predictive Value of Tests; D011347:Procollagen / Q000097:blood; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D012044:Regression Analysis; D012680:Sensitivity and Specificity; D019714:Tissue Inhibitor of Metalloproteinases
D015415:Biomarkers; D006023:Glycoproteins; D061965:Matrix Metalloproteinase Inhibitors; D010446:Peptide Fragments; D011347:Procollagen; D019714:Tissue Inhibitor of Metalloproteinases; C041876:procollagen Type III-N-terminal peptide; D003094:Collagen